DENVER, June 17 Corgenix Medical Corporation(OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostictest kits, announced today the appointment of Barry L. Molk, M.D., F.A.C.C.,and Charles H. Miranda, M.D., F.A.C.P., F.A.A.P., to its scientific advisoryboard.
Drs. Molk and Miranda join Luis Lopez, M.D., Corgenix Chairman and ChiefMedical Officer, expanding the number of scientific advisory board members tothree.
"These two individuals bring a wealth of knowledge and expertise to ourorganization," said Douglass Simpson, Corgenix' President and Chief ExecutiveOfficer. "Their appointment strengthens the clinical and scientific guidancerequired for the successful development, manufacturing and marketing of ourdiagnostic testing products."
Dr. Molk has been affiliated with Aurora Denver Cardiology Associatessince 1976 and has served as Chief of Cardiology at Sky Ridge Medical Centersince 2003. He is board certified in internal medicine and cardiovasculardiseases and is also a Fellow of the American College of Cardiology(F.A.C.C.).
After receiving his medical degree from the University of Colorado HealthSciences Center (UCHSC), Dr. Molk completed his residency training at BaylorAffiliated Hospitals and UCHSC, and is fellowship trained in cardiology fromUCHSC. He maintains a teaching appointment as Associate Clinical Professor ofMedicine, UCHSC.
Dr. Miranda is currently in private practice in internal medicine andpediatrics at South Denver Internal Medicine and Pediatrics, P.C. in Denver.Previously, he practiced internal medicine and pediatrics for 10 years at theworld-renowned Texas Medical Center in Houston. Miranda is board certified bythe American Board of Internal Medicine and the American Board of Pediatrics.He is a Fellow of the American Academy of Pediatrics (F.A.A.P.) and theAmerican College of Physicians (F.A.C.P.).
Dr. Miranda received his medical degree from the University of California,San Francisco (UCSF). He completed specialty training in both internalmedicine and pediatrics at Baylor College of Medicine in Houston, Texas. He isalso a clinical instructor in the department of medicine at UCHSC.
Corgenix periodically draws on the expertise of advisors and consultantsin fields related to its technology and markets. These members are availableto Corgenix as needed on an individual basis to provide advice with respect toclinical medicine and other matters requiring scientific expertise.Non-employee members of the scientific advisory board are compensated fortheir participation.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specializeddiagnostic kits for immunology disorders, vascular diseases and bone and jointdisorders. Corgenix diagnostic products are commercialized for use in clinicallaboratories throughout the world. The company currently sells over 50diagnostic products through a global distribution network. More information isavailable at http://www.corgenix.com.
Statements in this press release that are not strictly historical factsare "forward-looking" statements (identified by the words "believe","estimate", "project", "expect" or similar expressions) within the meaning ofthe Private Securities Litigation Reform Act of 1995. These statementsinherently involve risks and uncertainties that could cause actual results todiffer materially from the forward-looking statements. Factors that wouldcause or contribute to such differences include, but are not limited to,continued acceptance of the Company's products and services in themarketplace, competitive factors, changes in the regulatory environment, andother risks detailed in the Company's periodic report filings with theSecurities and Exchange Commission. The statements in this press release aremade as of today, based upon information currently known to